{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:34:18Z","timestamp":1778600058469,"version":"3.51.4"},"reference-count":32,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2004,3,16]],"date-time":"2004-03-16T00:00:00Z","timestamp":1079395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> High\u2010dose intravenous immunoglobulin (IVIG) is emerging as a promising new therapy for treating the rare but potentially fatal drug reaction toxic epidermal necrolysis (TEN). Experimental <jats:italic>in vitro<\/jats:italic> studies support that IVIG can block the Fas\u2010FasL\u2010mediated apoptosis in TEN.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Twelve consecutive patients (7M, 5F) with TEN admitted over a 5\u2010year period from January 1998 to December 2002 were treated with a dose of 0.5\u20131.0\u00a0g\/kg\/d of IVIG for 4\u20135\u00a0days along with standard care protocol. Clinical outcome in terms of average duration to arrest the progression, complete healing, hospital stay, side\u2010effects and complications were determined to find the efficacy of IVIG treatment.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Average age was 27.16\u00a0years (7\u201350\u00a0years). There were four children (2M, 2F) aged 7\u201312 years. One patient had an underlying malignancy. No patient had HIV infection. The average total body surface area involvement was 57.5% (30\u201390%). An IVIG infusion was started, on average, 1.58\u00a0days (1\u20133\u00a0days) after admission. All patients responded well to the treatment. There was no mortality. The disease progression was arrested in a mean of 2.83\u00a0days (1\u20135\u00a0days). Time taken for complete healing (re\u2010epithelialization) was 7.33\u00a0days (5\u201313\u00a0days). The average duration of hospital stay was 12.5\u00a0days (7\u201321 days). No side\u2010effects of the IVIG treatment were observed in these patients.<\/jats:p><jats:p>The drugs triggering TEN in these patients were phenytoin (four patients), followed by penicillin (three), cotrimoxazole (two), phenobarbital and furosemide (one patient each), respectively. In one patient, the offending drug could not be ascertained.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Our experience of treating 12 patients with TEN using IVIG, in Kuwait, confirms that it is a safe and effective treatment for these patients.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2004.02048.x","type":"journal-article","created":{"date-parts":[[2004,11,2]],"date-time":"2004-11-02T14:24:10Z","timestamp":1099405450000},"page":"847-851","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis"],"prefix":"10.1111","volume":"43","author":[{"given":"N","family":"Al\u2010Mutairi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshi","family":"Arun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nour\u2010Eldin","family":"Osama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaki","family":"Amr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al\u2010Sheltawy","family":"Mazen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u2010Adawy","family":"Ibtesam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u2010Baghly","family":"Nazeha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,3,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/22.6.450"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004630-200021030-00004"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11369-1"},{"key":"e_1_2_6_6_2","first-page":"357","article-title":"The drug hypersensitivity syndrome. What is the pathogenesis?","volume":"137","author":"Sullivan JR","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_7_2","unstructured":"BreathnachSM.Drug Reactions. In:ChampionRH BurtonJL BurnsDA eds.Textbook of Dermatology.6th edn. London: Blackwell Science Ltd 1998:3349\u20133512."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1996.tb06976.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5388.490"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)80199-0"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.1999.00347.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03276.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051702"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.127249"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.1.26"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.1.33"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.1.39"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12388434"},{"key":"e_1_2_6_19_2","first-page":"352","article-title":"The estimation of areas of burns","volume":"79","author":"Lund CC","year":"1944","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb02163.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(08)80969-3"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","article-title":"Plasmapheresis in severe drug\u2010induced toxic epidermal necrolysis","volume":"121","author":"Kamanbroo D","year":"1985","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb02175.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(85)80012-8"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198611000-00001"},{"key":"e_1_2_6_26_2","first-page":"273","article-title":"Burn center care for patients with toxic epidermal necrolysis","volume":"180","author":"Kelemen JJ","year":"1995","journal-title":"J Am Coll Surg"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)02197-7"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.4.300"},{"key":"e_1_2_6_29_2","first-page":"555","article-title":"The use of intravenous high\u2010dose immunoglobulins in a case of Stevens\u2013Johnson syndrome","volume":"14","author":"Amato GM","year":"1992","journal-title":"Pediatr Med Chir"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00061.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.1.85"},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1067\/mjd.2001.112325","article-title":"High\u2010dose intravenous immunoglobulins: An approach to treat severe immune mediated and autoimmune diseases of the skin","volume":"44","author":"Rutter A","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_33_2","first-page":"145","article-title":"Keratinocyte injury in drug\u2013induced toxic epidermal necrolysis. simultaneous but distinct topographic expression of CD95R and calprotectin","volume":"10","author":"Paquet P","year":"2002","journal-title":"Int J Mol Med"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2004.02048.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2004.02048.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T05:37:13Z","timestamp":1697348233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2004.02048.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,22]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1111\/j.1365-4632.2004.02048.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02048.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,22]]},"assertion":[{"value":"2004-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}